



FW

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
Group Art Unit (Not yet assigned)

I, Nanci A. Musich, hereby certify that this correspondence is being deposited with the US Postal Service as first class mail in an envelope addressed to Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date of my signature.


Signature

AUGUST 8, 2006
Date of Signature

Patent Application of

David L. Epstein

Application No. 10/580,477

Confirmation No.: Not yet assigned

Filed: May 24, 2006

Examiner: Not yet assigned

"A METHOD OF PREVENTING OR
TREATING GLAUCOMA"

INFORMATION DISCLOSURE STATEMENT
PURSUANT TO 37 CFR §1.97(b)(3)


Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

The Examiner's attention is directed to the references which are listed on the attached Form PTO/SB/08A and/or PTO/SB/08B and copies of non-U.S. patent references are attached. Citation of these references is respectfully requested.

No concession is made that these documents are prior art, and Applicant expressly reserves the right to antedate the documents as may be appropriate.

Respectfully submitted,


Gregory J. Hartwig
Reg. No. 46,761

File No. 017425-9004-01

Michael Best & Friedrich LLP
100 East Wisconsin Avenue, Suite 3300
Milwaukee, Wisconsin 53202-4108
414.271.6560

T:\client\017425\9004\A 1656877.1

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary) Sheet 1 of 4		Complete if Known <table border="1"> <tr> <td>Application Number</td> <td>10/580,477</td> </tr> <tr> <td>Filing Date</td> <td>May 24, 2006</td> </tr> <tr> <td>First named Inventor</td> <td>David L. EPSTEIN</td> </tr> <tr> <td>Group Art Unit</td> <td>Not yet assigned</td> </tr> <tr> <td>Examiner name</td> <td>Not yet assigned</td> </tr> <tr> <td>Attorney Docket Number</td> <td>017425-9004-01</td> </tr> </table>		Application Number	10/580,477	Filing Date	May 24, 2006	First named Inventor	David L. EPSTEIN	Group Art Unit	Not yet assigned	Examiner name	Not yet assigned	Attorney Docket Number	017425-9004-01
Application Number	10/580,477														
Filing Date	May 24, 2006														
First named Inventor	David L. EPSTEIN														
Group Art Unit	Not yet assigned														
Examiner name	Not yet assigned														
Attorney Docket Number	017425-9004-01														
U.S. Patent Documents															
Examiner Initials	U.S. Patent Document Number	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document												
	3,983,140	Endo et al.	09/28/1976												
	4,231,938	Monaghan et al.	11/04/1980												
	4,346,227	Terahara et al.	08/24/1982												
	4,444,784	Hoffman et al.	04/24/1984												
	4,450,171	Hoffman et al.	05/22/1984												
	4,681,893	Roth	07/21/1987												
	4,739,073	Kathawala	04/19/1988												
	5,041,450	Chiou et al.	08/20/1991												
	5,134,124	Nisato et al.	07/28/1992												
	5,177,080	Angerbauer et al.	01/05/1993												
	5,273,995	Roth	12/28/1993												
	5,284,953	Ohara et al.	02/08/1994												
	5,354,772	Kathawala	10/11/1994												
	5,356,896	Kabadi et al.	10/18/1994												
	5,536,814	Ruoslahti et al.	07/16/1996												
	5,629,294	diZerega et al.	05/13/1997												
	5,683,867	Biesecker et al.	11/04/1997												
	5,733,558	Breton et al.	03/31/1998												
Examiner Signature			Date Considered												

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer. Patent and Trademark Office, Washington, DC 0231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary) Sheet 2 of 4		Complete if Known		
		Application Number	10/580,477	
		Filing Date	May 24, 2006	
		First named Inventor	David L. EPSTEIN	
		Group Art Unit	Not yet assigned	
		Examiner name	Not yet assigned	
		Attorney Docket Number	017425-9004-01	
U.S. Patent Documents				
Examiner Initials		U.S. Patent Document Number	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document
		5,753,230	Brooks et al.	05/19/1998
		5,811,515	Grubbs et al.	09/22/1998
		5,856,336	Fujikawa et al.	01/05/1999
		5,900,414	Sugrue et al.	05/04/1999
		2003/0207925	Cameron et al.	11/06/2003
		2005/0239871	Hellberg et al.	10/27/2005

FOREIGN PATENT DOCUMENTS							
Examiner Initials		Country Code	Foreign Patent Document Number	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document	Translation	English Abstract
		EP	363,934	Sandoz AG	04/18/1990		
		EP	491,226	Bayer AG	06/24/1992		X
		EP	738,510	Oreal	10/23/1996		X
		JP	10-17488	Asahi Glass Co., Ltd.	01/20/1998	X	
		WO	97/06791	The Scripps Research Institute	02/27/1997		
		WO	2005/105155	Saitama Medical School	11/10/2005		

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer. Patent and Trademark Office, Washington, DC 0231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO	Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary) Sheet 3 of 4	Application Number	10/580,477
	Filing Date	May 24, 2006
	First named Inventor	David L. EPSTEIN
	Group Art Unit	Not yet assigned
	Examiner name	Not yet assigned
	Attorney Docket Number	017425-9004-01
U.S. Patent Documents		

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, pages(s), volume-issue numbers(s), publisher, city and/or country where published.
	Collaborative Normal-Tension Glaucoma Study Group, "Comparison of Glaucomatous Progression Between Untreated Patients with Normal-Tension Glaucoma and Patients with Therapeutically Reduced Intraocular Pressures," <i>American Journal of Ophthalmology</i> , vol. 126, no. 4, October 1998, pages 487-97, Elsevier Science Inc., 1998.
	Avila, Marcel, et al., "The Effects of RGD (Arg-Gly-Asp) Peptides on Glaucoma Filtration Surgery in Rabbits," <i>Ophthalmic Surgery and Lasers</i> , April 1998, vol. 29, no. 4, pages 309-17.
	Comparato, C., et al., "Clinically relevant pleiotropic effects of statins: Drug properties or effects of profound cholesterol reduction?" <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , vol. 11, no. 5, October 2001, pages 328-43, Medikal Press s.r.l., Milan, Italy.
	Edwards, Peter A., and Johan Ericsson, "Sterols and Isoprenoids: Signaling Molecules Derived from the Cholesterol Biosynthetic Pathway," <i>Annual Review of Biochemistry</i> , vol. 68, 1999, pages 157-85, Annual Reviews, Palo Alto, California.
	Hall, Nigel F., et al., "Risk of macular degeneration in users of statins: cross sectional study," <i>BMJ</i> , 2001, 323 (7309), pages 375-76, http://bmj.bmjjournals.com/cgi/content/full/323/7309/375 .
	HersHKoviz, Rami, et al., "Nonpeptidic Analogues of the Arg-Gly-Asp (RGD) Sequence Specifically Inhibit the Adhesion of Human Tenon's Capsule Fibroblasts to Fibronectin," <i>Investigative Ophthalmology & Visual Science</i> , April 1994, vol. 35, no. 5, pages 2585-91, Association for Research in Vision and Ophthalmology.
	Kagansky, N., et al., "Cholesterol lowering in the older population: time for reassessment?," <i>QJM</i> , vol. 94, no. 9, September 2001, pages 457-63, Oxford University Press, Association of Physicians, 2001.
	Kass, Michael A., "The Ocular Hypertension Treatment Study," <i>Archives of Ophthalmology</i> , vol. 120, June 2002, pages 701-13, American Medical Association.
	Laties, Alan M., et al., "Expanded Clinical Evaluation of Lovastatin (EXCEL) Study Results II. Assessment of the Human Lens After 48 Weeks of Treatment with Lovastatin," <i>The American Journal of Cardiology</i> , March 1, 1991, vol. 67, no. 6, pages 447-53.
	Lowenstein, John M., ed., <i>Methods in Enzymology</i> , "Lipids," Part C, vol. 71, pages 455-509, Academic Press, Inc., New York, 1981.
	McCarty, Catherine A., et al., "Cholesterol-lowering medications reduce the risk of age-related maculopathy progression," <i>The Medical Journal of Australia</i> , vol. 175, no. 6, 17 September 2001, page 340, Australian Medical Association.

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer. Patent and Trademark Office, Washington, DC 0231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary) Sheet 4 of 4		Application Number	10/580,477
		Filing Date	May 24, 2006
		First named Inventor	David L. EPSTEIN
		Group Art Unit	Not yet assigned
		Examiner name	Not yet assigned
		Attorney Docket Number	017425-9004-01
U.S. Patent Documents			
		McGwin, Gerald, Jr., et al., "Statins and Other Cholesterol-Lowering Medications and the Presence of Glaucoma," <i>Arch Ophthalmol</i> , vol. 122, June 2004, pages 822-26.	
		McGwin, Gerald, Jr., et al., "The association between statin use and age related maculopathy," <i>British Journal of Ophthalmology</i> , 2003; 87, pages 1121-25, from www.bjophthalmol.com , 6 July 2006.	
		Pardridge, William M., <i>Peptide Drug Delivery to the Brain</i> , page 247, Raven Press, New York, 1991.	
		Rao, P. Vasantha, et al., "Modulation of Aqueous Humor Outflow Facility by the Rho Kinase-Specific Inhibitor Y-27632," <i>Investigative Ophthalmology & Visual Science</i> , vol. 42, no. 5, April 2001, pages 1029-37, Association for Research in Vision and Ophthalmology.	
		Ruoslahti, Erkki, and Michael D. Pierschbacher, "Arg-Gly-Asp: A Versatile Cell Recognition Signal," <i>Cell</i> , Vol 44, 517-18, February 28, 1986, Cell Press, 1986.	
		Schlienger, Raymond G., et al., "Risk of Cataract in Patients Treated with Statins," <i>Archives of Internal Medicine</i> , vol. 161, September 10, 2001, pages 2021-26, American Medical Association, Chicago, IL.	
		Shovman, Ora, et al., "Antiinflammatory and Immunomodulatory Properties of Statins," <i>Immunologic Research</i> , 25/3, pages 271-85, Humana Press Inc., 2002.	
		Song, Julia, et al., "Effects of Cholesterol-Lowering Statins on the Aqueous Humor Outflow Pathway," <i>Investigative Ophthalmology & Visual Science</i> , July 2005, vol. 46, no. 7, pages 2424-32, Association for Research in Vision and Ophthalmology.	
		Song, Julia, et al., "Effects of cholesterol lowering statin drugs on the aqueous humor outflow pathways," webpage: http://www.abstractsonline.com/viewer/viewAbstractPrintFriendly.asp?CKev={56E3C070-... 4/6/2004. Oasis. Online Abstract Submission and Invitation System – Program Planner, one page abstract.	
		Takemoto, Masao, and James K. Liao, "Pleiotropic Effects of 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibitors," <i>Journal of the American Heart Association</i> , vol. 21, no. 11, November 2001, pages 1712-19. American Heart Association, Inc., 2001.	
		Yalpani, Manssur, "Cholesterol-lowering drugs," <i>Chemistry & Industry</i> , no. 3, 5 February 1996, pages 85-89, Society of Chemical Industry, East Sussex, UK.	

T:\client\017425\9004\A1594925.1

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer. Patent and Trademark Office, Washington, DC 0231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box Alexandria, VA 22313-1450.